1. Home
  2. ITRM vs LEO Comparison

ITRM vs LEO Comparison

Compare ITRM & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITRM
  • LEO
  • Stock Information
  • Founded
  • ITRM 2015
  • LEO 1987
  • Country
  • ITRM Ireland
  • LEO United States
  • Employees
  • ITRM N/A
  • LEO N/A
  • Industry
  • ITRM Biotechnology: Pharmaceutical Preparations
  • LEO Trusts Except Educational Religious and Charitable
  • Sector
  • ITRM Health Care
  • LEO Finance
  • Exchange
  • ITRM Nasdaq
  • LEO Nasdaq
  • Market Cap
  • ITRM 40.0M
  • LEO 363.8M
  • IPO Year
  • ITRM 2018
  • LEO N/A
  • Fundamental
  • Price
  • ITRM $1.16
  • LEO $5.87
  • Analyst Decision
  • ITRM Strong Buy
  • LEO
  • Analyst Count
  • ITRM 2
  • LEO 0
  • Target Price
  • ITRM $7.00
  • LEO N/A
  • AVG Volume (30 Days)
  • ITRM 583.9K
  • LEO 200.2K
  • Earning Date
  • ITRM 08-13-2025
  • LEO 01-01-0001
  • Dividend Yield
  • ITRM N/A
  • LEO 4.01%
  • EPS Growth
  • ITRM N/A
  • LEO N/A
  • EPS
  • ITRM N/A
  • LEO 0.04
  • Revenue
  • ITRM N/A
  • LEO N/A
  • Revenue This Year
  • ITRM N/A
  • LEO N/A
  • Revenue Next Year
  • ITRM $270.19
  • LEO N/A
  • P/E Ratio
  • ITRM N/A
  • LEO $152.00
  • Revenue Growth
  • ITRM N/A
  • LEO N/A
  • 52 Week Low
  • ITRM $0.81
  • LEO $4.98
  • 52 Week High
  • ITRM $3.02
  • LEO $6.50
  • Technical
  • Relative Strength Index (RSI)
  • ITRM 61.00
  • LEO 49.33
  • Support Level
  • ITRM $0.91
  • LEO $5.90
  • Resistance Level
  • ITRM $1.03
  • LEO $6.00
  • Average True Range (ATR)
  • ITRM 0.05
  • LEO 0.05
  • MACD
  • ITRM 0.01
  • LEO 0.01
  • Stochastic Oscillator
  • ITRM 95.18
  • LEO 40.91

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

About LEO BNY Mellon Strategic Municipals Inc.

BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others. BNY Mellon and its affiliates, including BNYM Investment Adviser, INA and others involved in the management, sales, investment activities, business operations or distribution of the Fund, are engaged in businesses and have interests other than that of managing the Fund.

Share on Social Networks: